Evidence in Treatment of PH due to Lung Disease
28 Dec, 23
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide9.jpg?updated=20231228111018)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide1.jpg?updated=20231228111012)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide10.jpg?updated=20231228111019)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide11.jpg?updated=20231228111020)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide2.jpg?updated=20231228111013)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide3.jpg?updated=20231228111013)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide4.jpg?updated=20231228111014)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide5.jpg?updated=20231228111015)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide6.jpg?updated=20231228111016)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide7.jpg?updated=20231228111017)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide8.jpg?updated=20231228111017)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide9.jpg?updated=20231228111018)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide1.jpg?updated=20231228111012)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide10.jpg?updated=20231228111019)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide11.jpg?updated=20231228111020)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide2.jpg?updated=20231228111013)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide3.jpg?updated=20231228111013)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide4.jpg?updated=20231228111014)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide5.jpg?updated=20231228111015)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide6.jpg?updated=20231228111016)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide7.jpg?updated=20231228111017)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide8.jpg?updated=20231228111017)
![image NP](/-/media/ciplamed/slidelibrary/images/whats-new-in-group-3ph_-2023/slide9.jpg?updated=20231228111018)
Slide 1/11
This presentation summarises available evidence on management of pulmonary hypertension in patients with group 3 PH.
More From Area Of Interest
You may also like
Our Research
23 Nov, 23
![CiplaMedLogo](/-/media/ciplamed/contentmigration/news/image/asthma_4.jpg?updated=20221117192612)
23 Nov, 23
![CiplaMedLogo](/-/media/ciplamed/nar3.webp?updated=20230925072442)
2 Nov, 23
Our Research
5 Oct, 23
![CiplaMedLogo](/-/media/ciplamed/synchrobreathe.webp?updated=20231005104421)
5 Oct, 23
![CiplaMedLogo](/-/media/ciplamed/journal-scan-image/a-systematic-review-on-role-of-ics-on-an-intermittent-or-as-needed-basis-in-pediatric-asthma.webp?updated=20230109104319)
5 Oct, 23
![CiplaMedLogo](/-/media/ciplamed/correction-images/nasthma5.webp?updated=20230302111423)
3 Oct, 23
![CiplaMedLogo](/-/media/ciplamed/contentmigration/news/image/acne_1.jpg?updated=20221117192902)
6 Jun, 23
Latest Items
Journal Scans
11 Jul, 24
![CiplaMedLogo](/-/media/ciplamed/nip2.webp?updated=20240527063806)
11 Jul, 24
Journal Scans
11 Jul, 24
![CiplaMedLogo](/-/media/ciplamed/necg3.webp?updated=20240711053251)
11 Jul, 24
![CiplaMedLogo](/-/media/ciplamed/ndiabret2.webp?updated=20240527063801)
10 Jul, 24